Observer Blinded, Randomised Study to Investigate Safety, Tolerability and Long-term Immunogenicity of Different Dose Regimens and Formulations of MV-CHIK in Healthy Volunteers
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Chikungunya virus vaccine (Primary)
- Indications Chikungunya virus infections
- Focus Pharmacodynamics
- Sponsors Themis Bioscience
- 28 Jan 2019 Planned primary completion date changed from 10 Dec 2018 to 10 Oct 2019.
- 10 Dec 2018 Status changed from not yet recruiting to recruiting.
- 24 Aug 2018 New trial record